AZNCF News and Press, AstraZeneca Plc From 02/08/24

2024-02-08 15:10:05 ET AstraZeneca PLC (AZN) Q4 2023 Earnings Conference Call February 8, 2024, 06:45 AM ET Company Participants Andy Barnett - Head, IR Pascal Soriot - CEO Aradhana Sarin - CFO David Fredrickson - EVP, Oncology Business Susan Galbraith - ...

2024-02-08 02:23:16 ET AstraZeneca's Q4 Earnings: Recognizing The Underrated Gem's Growth Why AstraZeneca's Gracell Biotechnologies Acquisition Is A Win-Win AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition AstraZeneca to invest $300M in new US cell ...

2024-02-07 18:00:06 ET Summary Eli Lilly and Company has seen significant growth and generated strong returns, outperforming the S&P 500. The company's revenue increased by 28.1% in the final quarter of 2023, exceeding analysts' expectations. While some drugs, like Trulici...

2024-02-04 09:21:56 ET Summary AstraZeneca is one of the fastest-growing pharmaceutical companies. On February 8, 2024, the company will publish financial results for the 4th quarter of 2023. From a broader perspective, AstraZeneca's EPS is expected to continue to grow through...

2024-02-03 11:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Global markets rallied...

2024-01-28 20:15:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron International Growth Fund® (the Fund) gained 7.78% (Institutional Shares) d...

2024-01-22 10:08:03 ET Summary While UK stocks are currently valued lower than their U.S. counterparts, a closer examination reveals concerns such as stagnant financial and energy companies with limited growth potential. In contrast, UK small and mid-cap companies show more promis...

2024-01-22 08:50:51 ET Summary Positive preliminary results were achieved in early-stage studies of its protein degraders, NX-2127 and NX-5948, for the treatment of B-cell malignancies. Protein degradation platform offers several advantages over other BTK drugs, such as ability to...

2024-01-21 01:55:00 ET Summary Lee’s Pharm acquired China rights to a heart failure therapy from Windtree Therapeutics. AstraZeneca signed an investment cooperation agreement with the Taizhou National Medical High-tech Development Zone to build a new production line in its ...

2024-01-09 18:04:24 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...